Delcath Systems to Hold Investor Update on Focus Trial Data and Future Development Plans on December 2, 2021
06 November 2021 - 12:00AM
Delcath Systems, Inc. (Nasdaq:
DCTH ),
an interventional oncology company focused on the treatment of
primary and metastatic cancers of the liver, announced today it
will host a comprehensive Investor Update event on Thursday,
December 2nd, from 10:00am ET – 1:00pm ET.
The event will feature physicians discussing percutaneous
hepatic perfusion, updated Focus trial data and the role of
Hepzato™ Kit (melphalan hydrochloride for injection/Hepatic
Delivery System) as a potential treatment for patients with
hepatic-dominant metastatic ocular melanoma. Additionally,
physicians will discuss the potential utility of Hepzato in
treating colorectal cancer, intrahepatic cholangiocarcinoma, the
unmet need in liver metastases and related clinical development
strategies.
Event Details:
Event: Delcath Systems Virtual Investor Update
EventDate: Thursday, December 2, 2021Time: 10:00am – 1:00
p.m. EST
To register for this event, please click here.
The live webcast of the event may be accessed through the Events
and Presentation page of Delcath’s website, under the
Investors section. The archived webcast and presentation will be
available on the Company’s website after the event.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, and is considered a
combination drug and device product regulated by the United States
Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical
device and is approved for sale under the trade name CHEMOSAT
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024